Search details
1.
Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases.
Int J Mol Sci
; 23(12)2022 Jun 18.
Article
in English
| MEDLINE | ID: mdl-35743246
2.
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.
Cancer Immunol Immunother
; 69(2): 315-324, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31915854
3.
B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.
Eur J Haematol
; 103(4): 351-361, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31297883
4.
Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8+T cells.
Front Immunol
; 14: 1151659, 2023.
Article
in English
| MEDLINE | ID: mdl-37275886
5.
Pre-existing TGF-ß-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.
J Immunother Cancer
; 11(3)2023 03.
Article
in English
| MEDLINE | ID: mdl-36948507
6.
Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.
Front Immunol
; 14: 1240678, 2023.
Article
in English
| MEDLINE | ID: mdl-37662956
7.
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.
Cancers (Basel)
; 15(17)2023 Aug 29.
Article
in English
| MEDLINE | ID: mdl-37686599
8.
An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Front Immunol
; 14: 1117466, 2023.
Article
in English
| MEDLINE | ID: mdl-36911725
9.
Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer.
Cancers (Basel)
; 15(14)2023 Jul 19.
Article
in English
| MEDLINE | ID: mdl-37509338
10.
Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis.
Front Oncol
; 13: 1176173, 2023.
Article
in English
| MEDLINE | ID: mdl-37223675
11.
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.
Front Immunol
; 14: 1122977, 2023.
Article
in English
| MEDLINE | ID: mdl-36999039
12.
Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression.
Front Immunol
; 13: 970322, 2022.
Article
in English
| MEDLINE | ID: mdl-35990670
13.
Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.
Front Immunol
; 13: 866610, 2022.
Article
in English
| MEDLINE | ID: mdl-35603202
14.
TGFß-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
J Immunother Cancer
; 10(12)2022 12.
Article
in English
| MEDLINE | ID: mdl-36600556
15.
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
J Immunother Cancer
; 10(10)2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36316062
16.
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Front Oncol
; 12: 1023015, 2022.
Article
in English
| MEDLINE | ID: mdl-36483037
17.
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Oncoimmunology
; 11(1): 2026020, 2022.
Article
in English
| MEDLINE | ID: mdl-35111385
18.
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Sci Transl Med
; 14(649): eaba4380, 2022 06 15.
Article
in English
| MEDLINE | ID: mdl-35704596
19.
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFß-expressing cancer cells in a TGFß-dependent manner.
Cell Mol Immunol
; 18(2): 415-426, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33408343
20.
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 27(12): 2212-2223, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34887574